Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients with Severe Preeclampsia: A Randomized, Single-Blind, Controlled Trial

Gilberto Arias-Hernández, Cruz Vargas-De-León, Claudia C Calzada-Mendoza, María Esther Ocharan-Hernández, Gilberto Arias-Hernández, Cruz Vargas-De-León, Claudia C Calzada-Mendoza, María Esther Ocharan-Hernández

Abstract

Background: Postpartum preeclampsia is a serious disease related to high blood pressure that occurs commonly within the first six days after delivery.

Objective: To evaluate if diltiazem improves blood pressure parameters in early puerperium patients with severe preeclampsia. Methodology. A randomized, single-blind longitudinal clinical trial of 42 puerperal patients with severe preeclampsia was carried out. Patients were randomized into two groups: the experimental group (n = 21) received diltiazem (60 mg) and the control group (n = 21) received nifedipine (10 mg). Both drugs were orally administered every 8 hours. Systolic, diastolic, and mean blood pressures as well as the heart rate were recorded and analyzed (two-way repeated measures ANOVA) at baseline and after 6, 12, 18, 24, 30, 36, 42, and 48 hours. Primary outcome measures were all the aforementioned blood pressure parameters. Secondary outcome measures included the number of hypertension and hypotension episodes along with the length of stay in the intensive care unit.

Results: No statistical differences were found between groups (diltiazem vs. nifedipine) regarding basal blood pressure parameters. Interarm differences in blood pressure (systolic, diastolic, and mean) and heart rate were statistically significant between treatment groups from 6 to 48 hours. Patients in the diltiazem group had lower blood pressure levels than patients in the nifedipine group. Significantly, patients who received diltiazem had fewer hypertension and hypotension episodes and stayed fewer days in the intensive care unit than those treated with nifedipine.

Conclusions: Diltiazem controlled arterial hypertension in a more effective and uniform manner in patients under study than nifedipine. Patients treated with diltiazem had fewer collateral effects and spent less time in the hospital. This trial is registered with NCT04222855.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2020 Gilberto Arias-Hernández et al.

Figures

Figure 1
Figure 1
CONSORT chart for a trial of diltiazem and nifedipine for the control of blood pressure in puerperal patients with severe preeclampsia.
Figure 2
Figure 2
Systolic and diastolic blood pressure during 48 hours of observation, showing that both drugs reduced blood pressure. The decrease was greater with diltiazem. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.001. Values expressed as the means ± 2SEM were evaluated by repeated measures ANOVA.
Figure 3
Figure 3
Mean blood pressure based on measurements of blood pressure with data sampled at 6-hour intervals for 48 hours, showing that both drugs lowered blood pressure. However, the reduction was greater with diltiazem. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.001. Values expressed as the means ± 2SEM were evaluated by repeated measures ANOVA.
Figure 4
Figure 4
Average of heart rate during 48 hours of observation, showing distinct patterns for each drug with an increase and a decrease for patients with nifedipine and diltiazem, respectively. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. Values expressed as the means ± 2SEM were evaluated by repeated measures ANOVA.

References

    1. Betrán A. P., Wojdyla D., Posner S. F., Gülmezoglu A. M. National estimates for maternal mortality: an analysis based on the WHO systematic review of maternal mortality and morbidity. BMC Public Health. 2005;5(1):p. 131. doi: 10.1186/1471-2458-5-131.
    1. Bilano V. L., Ota E., Ganchimeg T., Mori R., Souza J. P. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low-and middle-income countries: a WHO secondary analysis. PLoS One. 2014;9(3) doi: 10.1371/journal.pone.0091198.e91198
    1. Ghulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia. Seminars in Perinatology. 2012;36(1):56–59. doi: 10.1053/j.semperi.2011.09.011.
    1. Sibai B. M. Etiology and management of postpartum hypertension-preeclampsia. American Journal of Obstetrics and Gynecology. 2012;206(6):470–475. doi: 10.1016/j.ajog.2011.09.002.
    1. Falco M. L., Sivanathan J., Laoreti A., Thilaganathan B., Khalil A. Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology. 2017;50(3):295–301. doi: 10.1002/uog.17494.
    1. Frishman W. H., Veresh M., Schlocker S. J., Tejani N. Pathophysiology and medical management of systemic hypertension in preeclampsia. Cardiology in Review. 2005;13(6):274–284. doi: 10.1097/.
    1. Livingston J. C., Maxwell B. D. Preeclampsia: theories and speculations. Wiener Klinische Wochenschrift. 2003;115(5-6):145–148. doi: 10.1007/bf03040298.
    1. Gyselaers W., Thilaganathan B. Preeclampsia: a gestational cardiorenal syndrome. The Journal of Physiology. 2019;597(18):4695–4714. doi: 10.1113/JP274893.
    1. Thilaganathan B., Kalafat E. Cardiovascular system in preeclampsia and beyond. Hypertension. 2019;73(3):522–531. doi: 10.1161/HYPERTENSIONAHA.118.11191.
    1. Detección D. Y T. De Enfermedades Hipertensivas Del Embarazo. Guía De Evidencias Y Recomendaciones: Guía De Práctica Clínica. México City, Mexico: IMSS; 2017. .
    1. Firoz T., Magee L., MacDonell K., et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology. 2014;121(10):1210–1218. doi: 10.1111/1471-0528.12737.
    1. Shekhar S., Gupta N., Kirubakaran R., Pareek P. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2016;123(1):40–47. doi: 10.1111/1471-0528.13463.
    1. Sharma K. J., Greene N., Kilpatrick S. J. Oral labetalol compared to oral nifedipine for postpartum hypertension: a randomized controlled trial. Hypertension in Pregnancy. 2017;36(1):44–47. doi: 10.1080/10641955.2016.1231317.
    1. Veena P., Perivela L., Raghavan S. S. Furosemide in postpartum management of severe preeclampsia: a randomized controlled trial. Hypertension in Pregnancy. 2017;36(1):84–89. doi: 10.1080/10641955.2016.1239735.
    1. Magee L. A., Côté A.-M., Von Dadelszen P. Nifedipine for severe hypertension in pregnancy: emotion or evidence? Journal of Obstetrics and Gynaecology Canada. 2005;27(3):260–262. doi: 10.1016/s1701-2163(16)30519-9.
    1. Ellrodt A. G., Singh B. N. Clinical applications of slow channel blocking compounds. Pharmacology & Therapeutics. 1983;23(1):1–43. doi: 10.1016/0163-7258(83)90025-6.
    1. Tyldum E. V., Backe B., Støylen A., Slørdahl S. A. Maternal left ventricular and endothelial functions in preeclampsia. Acta Obstetricia et Gynecologica Scandinavica. 2012;91(5):566–573. doi: 10.1111/j.1600-0412.2011.01282.x.
    1. Hoyo-Vadillo C., Castañeda-Hernández G., Herrera J. E., et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. The Journal of Clinical Pharmacology. 1989;29(9):816–820. doi: 10.1002/j.1552-4604.1989.tb03425.x.
    1. Hong S., Akay S., Ayrik C., Cevik A. A. Adverse events associated with aggressive treatment of increased blood pressure. International Journal of Clinical Practice. 2004;58(5):517–519. doi: 10.1111/j.1368-5031.2004.00171.x.
    1. Basu S. K., Kinsey C. D., Miller A. J., Lahiri A. Improved efficacy and safety of controlled-release diltiazem compared to nifedipine may be related to its negative chronotropic effect. American Journal of Therapeutics. 2000;7(1):17–22. doi: 10.1097/00045391-200007010-00004.
    1. Ding Y., Vaziri N. D. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. The Journal of Pharmacology and Experimental Therapeutics. 2000;292(2):606–609.
    1. Pepine C. J., Feldman R. L., Whittle J., Curry R. C., Conti C. R. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. American Heart Journal. 1981;101(6):719–725. doi: 10.1016/0002-8703(81)90606-2.
    1. Balasubramaniam R., Chawla S., Mackenzie L., Schwiening C. J., Grace A. A., Huang C. L.-H. Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts. Pflugers Archiv-European Journal of Physiology. 2004;449(2):150–158. doi: 10.1007/s00424-004-1321-2.
    1. Klinke W. P., Kvill L., Dempsey E. E., Grace M. A randomized double-blind comparison of diltiazem and nifedipine in stable angina. Journal of the American College of Cardiology. 1988;12(6):1562–1567. doi: 10.1016/S0735-1097(88)80026-3.
    1. Glasser S. P., Gana T. J., Pascual L. G., Albert K. S. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. American Heart Journal. 2005;149(2):e1–e9. doi: 10.1016/j.ahj.2004.08.002.
    1. NORMA Oficial Mexicana NOM-007-SSA2-2016. Para la atención de la mujer durante el embarazo, parto y puerperio, y de la persona recién nacida.
    1. Poon L. C., Shennan A., Hyett J. A., et al. The international federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. International Journal of Gynecology & Obstetrics. 2019;145(S1):1–33. doi: 10.1002/ijgo.12802.
    1. Duley L., Meher S., Jones L. Drugs for Treatment of Very High Blood Pressure during Pregnancy (Review) Copyright © 2013 the Cochrane Collaboration. Hoboken, NJ, USA: John Wiley & Sons, Ltd; 2013.
    1. Frison L., Pocock S. J. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Statistics in Medicine. 1992;11(13):1685–1704. doi: 10.1002/sim.4780111304.
    1. Sedgwick P. Incidence rate ratio. BMJ. 2010;341:p. c4804. doi: 10.1136/bmj.c6085.
    1. Sroka C. J., Nagaraja H. N. Odds ratios from logistic, geometric, Poisson, and negative binomial regression models. BMC Medical Research Methodology. 2018;18(1):p. 112. doi: 10.1186/s12874-018-0568-9.
    1. Eiland E., Nzerue C., Faulkner M. Preeclampsia 2012. Journal of Pregnancy. 2012;2012:7. doi: 10.1155/2012/586578.586578
    1. Pennington K. A., Schlitt J. M., Jackson D. L., Schulz L. C., Schust D. J. Preeclampsia: multiple approaches for a multifactorial disease. Disease Models & Mechanisms. 2012;5(1):9–18. doi: 10.1242/dmm.008516.
    1. Barton J. R., Prevost R. R., Wilson D. A., Whybrew W. D., Sibai B. M. Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. American Journal of Obstetrics and Gynecology. 1991;165(4):951–954. doi: 10.1016/0002-9378(91)90446-x.
    1. Magee L. A., Abalos E., Von Dadelszen P., Sibai B., Easterling T., Walkinshaw S. How to manage hypertension in pregnancy effectively. British Journal of Clinical Pharmacology. 2011;72(3):394–401. doi: 10.1111/j.1365-2125.2011.04002.x.
    1. Magee L. A., Abalos E., Von Dadelszen P., Sibai B., Walkinshaw S. A. Control of hypertension in pregnancy. Current Hypertension Reports. 2009;11(6):429–436. doi: 10.1007/s11906-009-0073-y.
    1. Brown M. A., Lindheimer M. D., Swiet M. D., Assche A. V., Moutquin J.-M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the Study of hypertension in pregnancy (ISSHP) Hypertension in Pregnancy. 2001;20(1):IX–XIV. doi: 10.3109/10641950109152635.
    1. Brown M. A., Mangos G., Davis G., Homer C. The natural history of white coat hypertension during pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 2005;112(5):601–606. doi: 10.1111/j.1471-0528.2004.00516.x.
    1. Bombrys A., Barton J., Habli M., Sibai B. Expectant management of severe preeclampsia at 270/7 to 336/7 weeks’ gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. American Journal of Perinatology. 2009;26(6):441–446. doi: 10.1055/s-0029-1214243.
    1. Belfort M. A., Clark S. L., Sibai B. Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate. Obstetrical & Gynecological Survey. 2006;61(10):655–665. doi: 10.1097/01.ogx.0000238670.29492.84.
    1. Vermillion S. T., Scardo J. A., Newman R. B., Chauhan S. P. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. American Journal of Obstetrics and Gynecology. 1999;181(4):858–861. doi: 10.1016/s0002-9378(99)70314-5.
    1. Zulfeen M., Tatapudi R., Sowjanya R. IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2019;236:46–52. doi: 10.1016/j.ejogrb.2019.01.022.
    1. Grossman E., Messerli F. H. Calcium antagonists. Progress in Cardiovascular Diseases. 2004;47(1):34–57. doi: 10.1016/j.pcad.2004.04.006.
    1. Abernethy D. R. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology. 1992;80(1):31–36. doi: 10.1159/000175050.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner